Stockscreener 앱 받기
112.97
0.36%
0.41
시간 외 거래:
112.90
-0.07
-0.06%
전일 마감가:
$112.56
열려 있는:
$112.76
하루 거래량:
4.63M
Relative Volume:
0.68
시가총액:
$140.17B
수익:
$28.80B
순이익/손실:
$6.31B
주가수익비율:
22.50
EPS:
5.02
순현금흐름:
$9.37B
1주 성능:
-1.57%
1개월 성능:
-1.10%
6개월 성능:
+0.88%
1년 성능:
+42.19%
1일 변동 폭
$112.14
$113.24
1주일 범위
$112.14
$115.50
52주 변동 폭
$77.74
$121.83
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
GILD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
112.97 | 139.67B | 28.80B | 6.31B | 9.37B | 5.02 |
|
LLY
Lilly Eli Co
|
732.58 | 656.17B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
177.17 | 422.54B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
210.40 | 367.30B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.55 | 244.83B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.12 | 207.84B | 63.43B | 16.42B | 14.72B | 6.49 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
What earnings revisions data tells us about Gilead Sciences Inc.2025 Institutional Moves & High Yield Stock Recommendations - Newser
Gilead Sciences Inc. Recovery Likely Here’s What Data Shows getLinesFromResByArray error: size == 0 - thegnnews.com
Gilead Sciences’ SWOT analysis: HIV giant faces challenges, oncology promise - Investing.com
Is Gilead Sciences Inc. currently under institutional pressureTrade Entry Summary & Target Return Focused Picks - خودرو بانک
Stock Analysis | Gilead Sciences OutlookBullish Technicals and Mixed Analyst Signals - AInvest
Will Gilead Sciences Inc. stock go up soonQuarterly Portfolio Review & Free High Return Stock Watch Alerts - Newser
Technical analysis overview for Gilead Sciences Inc. stockQuarterly Profit Review & AI Based Buy and Sell Signals - Newser
Visual trend scoring systems applied to Gilead Sciences Inc.Fed Meeting & Fast Gain Stock Trading Tips - Newser
Gilead Sciences (GILD) Announces Marketing Authorization for Yeytuo from the European Commission - MSN
Forecasting Gilead Sciences Inc. price range with options dataJuly 2025 Breakouts & Smart Money Movement Tracker - Newser
Price action breakdown for Gilead Sciences Inc.Earnings Overview Summary & Safe Entry Trade Signal Reports - Newser
Will Gilead Sciences Inc. bounce back from current supportJuly 2025 Selloffs & Accurate Technical Buy Alerts - Newser
Paving the Way for the Future Pipeline: Gilead Builds New State-of-the-Art Research Center - Gilead Sciences
Gilead Climbs 0.36% on Strong-Buy Upgrade and Institutional Buys Despite 174th-Ranked 0.52B Volume - AInvest
Gilead Sciences' Insider Selling: Liquidity Management or Early Warning Signal? - AInvest
Statistical indicators supporting Gilead Sciences Inc.’s strength2025 Key Lessons & Low Risk High Win Rate Stock Picks - Newser
Applying Wyckoff theory to Gilead Sciences Inc. stock2025 Geopolitical Influence & Advanced Technical Analysis Signals - Newser
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock - MSN
Does Gilead Sciences Inc. show high probability of rebound2025 Technical Patterns & Risk Controlled Daily Trade Plans - Newser
How hedge fund analytics apply to Gilead Sciences Inc. stock2025 Trading Recap & Daily Profit Maximizing Tips - Newser
Gilead Sciences Advances Ulcerative Colitis Treatment with GS-1427 Study - TipRanks
Gilead and Arcus Biosciences Complete Promising Cancer Study - TipRanks
HER2-Negative Metastatic Breast Cancer Market Positioned for Accelerated Development Through 2032, DelveInsight Finds | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai - The Globe and Mail
Gilead details discovery of oral integrin inhibitor GS-1427 - BioWorld MedTech
Using portfolio simulators with Gilead Sciences Inc. includedMarket Sentiment Report & Weekly Top Performers Watchlists - Newser
Will Gilead Sciences Inc. rebound enough to break even2025 Market Trends & Growth Focused Stock Pick Reports - Newser
Gilead Shares Plunge 0.72% as Trading Volume Tanks to 146th in $530M Turnover - AInvest
Gilead granted EU nod for twice-yearly HIV PrEP therapy - MSN
Analyst Says Gilead (GILD) is a ‘Very High Quality’ Cheap Stock – Here’s Why - MSN
US judge recuses herself from black-market drug case over Gilead stock purchases - Reuters
Those Who Invested in Gilead Sciences (NASDAQ:GILD) Three Years Ago Are up 105% - 富途牛牛
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.65%
0.92%
자본화:
|
볼륨(24시간):